"label","id","uuid:ID","name","identifier","instanceType","text","description"
"","EligibilityCriteria_1","04a713e2-f619-4a26-aea5-de145f024331","Age Criteria","1","ELIGIBILITY_CRITERIA","Subjects shall be between [min_age] and [max_age]","The study age criterion"
"","EligibilityCriteria_2","401179ca-4062-4f43-bda5-25e3976a2568","Pop Criteria","2","ELIGIBILITY_CRITERIA","[StudyPopulation] as defined by the NINCDS and the ADRDA guidelines (Attachment LZZT.7)","The study population criterion"
"","EligibilityCriteria_3","e0f77410-592c-4326-8b23-f1d746798d49","Diag Criteria","3","ELIGIBILITY_CRITERIA","[Activity1] score of 10 to 23","The study diagnosis criterion"
"","EligibilityCriteria_4","f28af39c-10bc-43de-a07f-6af30ad6879a","Previous Criteria","9","ELIGIBILITY_CRITERIA","Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.","The previous xanomeline TTS criterion"
